Lonza shared in a press release that previous studies have established the benefits of UC-II among older populations, while the findings show the benefit in younger populations of healthy subjects.
The randomized, double-blind, placebo-controlled clinical study investigated the effects of a 40 mg daily dose of UC-II undenatured type II collagen on active, healthy male and female subjects between the ages of 20 and 55 who were experiencing pain with physical activity. Joint flexibility, joint discomfort, and daily step count were evaluated over six months, and the findings were published in two separate papers—one focused onknee flexibilityand the second focused onjoint discomfort.
Lonza reported that t new research substantiates that UC-II undenatured type II collagen:
- Is clinically proven to significantly improve joint flexibility (15 times better than placebo) and helps joints feel 10 years younger by restoring 3.23 degrees of knee flexion
- Helps reduce joint discomfort after physical activity and significantly decreases knee discomfort when twisting/pivoting the knee, walking downstairs, and walking on a flat surface compared to placebo at 180 days.
- Makes walking more comfortable, helping people hit daily step goals. Subjects taking UC-II walked over 1/4 mile more per day compared with placebo.
